Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | WNT1 | P04628 | 2/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KHK | P50053 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12230388 | 1.00 | SCN3A (0.46) | SCN3ASCN9AGSK3BDYRK1AWNT1 | |
| SCHEMBL5754037 | 0.82 | NPC1 (0.50) | SCN3ASCN9AGSK3BDYRK1AWNT1 | |
| SCHEMBL3331893 | 0.82 | NPC1 (0.50) | SCN3ASCN9AGSK3BDYRK1AWNT1 | |
| SCHEMBL30052306 | 0.77 | HPGD (0.49) | SCN3ASCN9AGSK3BDYRK1AWNT1 | |
| SCHEMBL18555420 | 0.77 | RAB9A (0.53) | SCN9AGSK3BDYRK1AWNT1HPGD | |
| SCHEMBL23885369 | 0.77 | HPGD (0.49) | SCN3ASCN9AGSK3BDYRK1AWNT1 | |
| SCHEMBL15607640 | 0.77 | HPGD (0.49) | SCN3ASCN9AGSK3BDYRK1AWNT1 | |
| SCHEMBL12348732 | 0.77 | RAB9A (0.53) | SCN9AGSK3BDYRK1AWNT1HPGD | |
| SCHEMBL15129358 | 0.76 | SCN3A (0.48) | SCN3ASCN9AGSK3BDYRK1AWNT1 | |
| Hydrochloric Acid SCHEMBL18554952 | 0.76 | HPGD (0.48) | SCN3ASCN9AGSK3BDYRK1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896452-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-8044199-B2 | N-formyl hydroxylamines compounds | VICURON HOLDINGS LLC (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100063278-A1 | N-Formyl Hydroxylamines compounds | NOVARTIS AG (CH) | 2010-03-11 | — | — | US | disclosed |
| US-7615635-B2 | N-formyl hydroxylamines | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20090062537-A1 | N-Formyl Hydrozyamine Compounds | LEE KWANGHO | 2009-03-05 | — | — | US | disclosed |
| EP-1994027-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | Novartis AG (CH) | 2008-11-26 | — | — | EP | disclosed |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | VICURON HOLDINGS LLC | 2008-07-03 | — | — | US | disclosed |
| EP-1896452-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | Novartis Pharma AG. (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007106670-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| WO-2006127576-A2 | N - FORMYL HYDROXYLAMINE COMPOUNDS AS PDF INHIBITORS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063278-A1 | N-Formyl Hydroxylamines compounds | PDF, MMP2, HNMT | SCN3A 4217/4885SCN9A 4288/4885GSK3B 4629/4885 |
| US-20090062537-A1 | N-Formyl Hydrozyamine Compounds | PDF, HNMT, MMP2 | SCN3A 3414/4885SCN9A 3577/4885GSK3B 4574/4885 |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | PDF, MMP2, PEPD | SCN3A 4630/4885SCN9A 4645/4885GSK3B 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.